Effects of brodalumab on psoriasis and depressive symptoms in patients with insufficient response to TNF ‐α inhibitors

• Published in: Journal of dermatology Vol. 50; no. 11; pp. 1401 - 1414
• Main Authors: Andersch‐Björkman, Ylva, Micu, Emanuela, Seifert, Oliver, Lonne‐Rahm, Sol‐Britt, Gillstedt, Martin, Osmancevic, Amra
• Format: Journal Article
• Language: English
• Published: Tokyo Wiley Subscription Services, Inc 01.11.2023
• Subjects: Anxiety; brodalumab; depression; Dermatologi och venereologi; Dermatology and Venereal Diseases; IL-17 inhibitor; Interleukin 17; Mental depression; Monoclonal antibodies; Patients; Psoriasis; Quality of life; Skin diseases; Statistical analysis; Tumor necrosis factor; Tumor necrosis factor-TNF
• ISSN: 0385-2407; 1346-8138
• DOI: 10.1111/1346-8138.16917

Abstract The objective of this study was to evaluate emotions of depression and anxiety in psoriatic patients that due to insufficient response to tumor necrosis factor‐alpha inhibition (TNF‐α), underwent a treatment switch from TNF‐α to interleukin 17 inhibition using brodalumab. The Self‐rated Montgomery‐Asberg Depression Rating Scale and the Hospital Anxiety and Depression Scale were used to assess depression and anxiety. A total of 20 patients with psoriasis were enrolled in the study. They were monitored for a period of 3 months following the transition to brodalumab treatment. The results showed a significant improvement in both the Psoriasis Area and Severity Index as well as symptoms of depression; anxiety symptoms showed a reduction, though not statistically significant. Perhaps of more interest, the positive effects on depression and anxiety seem to be independent of the reduction in skin related psoriatic lesions. These findings highlight the importance of addressing depressive and anxiety symptoms, together with psoriasis severity and quality of life, when managing patients with psoriasis.